BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32900860)

  • 1. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
    Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.
    Li W; Zhang X; Zhang C; Yan J; Hou X; Du S; Zeng C; Zhao W; Deng B; McComb DW; Zhang Y; Kang DD; Li J; Carson WE; Dong Y
    Nat Commun; 2021 Dec; 12(1):7264. PubMed ID: 34907171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
    Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
    Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.
    Gough MJ; Crittenden MR; Sarff M; Pang P; Seung SK; Vetto JT; Hu HM; Redmond WL; Holland J; Weinberg AD
    J Immunother; 2010 Oct; 33(8):798-809. PubMed ID: 20842057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes.
    Chen X; Li D; Cao Y; Gao J; Jin H; Shan H
    Mol Pharm; 2019 Oct; 16(10):4252-4259. PubMed ID: 31454248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
    Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
    Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
    Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
    Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.
    Evans DE; Prell RA; Thalhofer CJ; Hurwitz AA; Weinberg AD
    J Immunol; 2001 Dec; 167(12):6804-11. PubMed ID: 11739496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
    Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
    Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial immunotherapy induces tumor-infiltrating CD8
    Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiation Augments the Local Anti-Tumor Effect of
    Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
    Front Immunol; 2021; 12():763888. PubMed ID: 34868010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
    Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
    Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Science gone translational: the OX40 agonist story.
    Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
    Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
    Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Jahan N; Talat H; Curry WT
    Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.